Clinical significance of immune cell and biomarker changes in liver cancer

Table 1 Comparison of blood cell analysis, blood biochemical indexes, and carcinoembryonic antigen indexes (mean ± SD)

Indicators	PLC group (n = 30)	Control group (n = 30)	t	P value
White blood cells (× 109/L)	5.89 ± 0.65	6.02 ± 0.73	0.728	0.469
Neutrophils (× 109/L)	3.41 ± 0.29	3.35 ± 0.24	0.873	0.386
Lymphocytes (× 109/L)	1.56 ± 0.45	2.01 ± 0.57	3.394	0.001
Red blood cells (× 1012/L)	4.21 ± 0.34	4.75 ± 0.39	5.716	< 0.001
Hemoglobin (g/L)	117.48 ± 12.54	146.33 ± 11.48	9.294	< 0.001
Blood platelets (× 109/L)	199.02 ± 18.36	198.46 ± 20.11	0.113	0.911
GPT (U/L)	76.54 ± 6.57	23.88 ± 3.15	39.586	< 0.001
GOT (U/L)	68.82 ± 5.33	20.46 ± 4.28	38.749	< 0.001
Total protein (g/L)	56.37 ± 6.88	71.52 ± 6.75	8.609	< 0.001
Albumin (g/L)	25.78 ± 3.13	41.33 ± 3.62	17.798	< 0.001
Globulin (g/L)	0.65 ± 0.11	1.03 ± 0.23	8.164	< 0.001
BUN (μmol/L)	4.61 ± 0.52	4.65 ± 0.47	0.313	0.756
Scr (μmol/L)	302.58 ± 26.79	299.47 ± 23.85	0.475	0.637
CEA (μg/L)	13.65 ± 1.88	2.84 ± 0.49	30.476	< 0.001

BUN: Blood urea nitrogen; CEA: Carcinoembryonic antigen; GOT: Glutamic oxalacetic transaminase; GPT: Glutamic-pyruvic transaminase; PLC: Primary liver cancer; Scr: Serum creatinine.